Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

https://www.tipranks.com/news/the-fly/curis-price-target-lowered-to-20-from-26-at-h-c-wainwright Regeneron (REGN) announced three-year data for EYLEA HD Injection 8 ...

(NASDAQ: REGN) today announced positive three-year (156-week) data for EYLEA HD® (aflibercept) Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular ...

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

as compared to their previous rate of fluid reaccumulation with EYLEA® (aflibercept) Injection 2 mg ...

(NASDAQ: REGN) today shared positive results from a three-year extension study of the Phase 3 PHOTON trial, demonstrating that EYLEA HD (aflibercept) Injection 8 mg sustained visual and anatomic ...

Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 ...

TARRYTOWN, N.Y. - Regeneron (NASDAQ:REGN) Pharmaceuticals, Inc. (NASDAQ: REGN) today shared positive results from a three-year extension study of the Phase 3 PHOTON trial, demonstrating that EYLEA HD ...

88% of EYLEA HD patients had a last assigned dosing interval of ≥12 weeks at week 156, while sustaining visual and anatomic improvements achieved in the first 96 weeks, in this extension study ...

U.S. drugmaker Regeneron Pharmaceuticals on Thursday reported weaker-than-expected quarterly sales of the higher dose version ...